Claudio Zamagni

Bologna, 40138, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 160 publications

Molecular Characterization of Endometrial Cancer Using a Laboratory-Developed Multi-Gene NGS Panel.

Molecular Characterization of Endometrial Cancer Using a Laboratory-Developed Multi-Gene NGS Panel.

Journal: International journal of molecular sciences

Published: June 06, 2026

Pattern-based interpretation of SOX2 expression in ovarian teratomas: avoiding diagnostic pitfalls in the distinction between immature and mature neuroectodermal elements.

Pattern-based interpretation of SOX2 expression in ovarian teratomas: avoiding diagnostic pitfalls in the distinction between immature and mature neuroectodermal elements.

Journal: Histopathology

Published: May 06, 2026

Inavolisib for PIK3CA-mutated advanced endometrial cancer: a multicentric, phase II, MITO END-4 trial.

Inavolisib for PIK3CA-mutated advanced endometrial cancer: a multicentric, phase II, MITO END-4 trial.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: April 27, 2026

The TRUST trial in ovarian cancer: a missed opportunity or a turning point? The position of the Italian MITO group.

The TRUST trial in ovarian cancer: a missed opportunity or a turning point? The position of the Italian MITO group.

Journal: Frontiers in oncology

Published: April 11, 2026

Tumor infiltrating lymphocytes as a predictor of adjuvant avelumab efficacy in patients with high-risk triple negative breast cancer.

Tumor infiltrating lymphocytes as a predictor of adjuvant avelumab efficacy in patients with high-risk triple negative breast cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 11, 2026

Integrating PIK3CA Testing into Clinical Practice for Advanced HR+/HER2- Breast Cancer: An Expert Consensus.

Integrating PIK3CA Testing into Clinical Practice for Advanced HR+/HER2- Breast Cancer: An Expert Consensus.

Journal: Breast (Edinburgh, Scotland)

Published: February 12, 2026

Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.

Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.

Journal: Lancet (London, England)

Published: February 04, 2026

Association between pathologic chemotherapy response score and pattern of recurrence in advanced high-grade serous ovarian cancer.

Association between pathologic chemotherapy response score and pattern of recurrence in advanced high-grade serous ovarian cancer.

Journal: The oncologist

Published: January 11, 2026

Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial.

Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: December 09, 2025

Leveraging Real-World Data From a Clinicogenomic Database Addresses the Treatment Gap in Patients With High-Grade Serous Ovarian Cancer.

Leveraging Real-World Data From a Clinicogenomic Database Addresses the Treatment Gap in Patients With High-Grade Serous Ovarian Cancer.

Journal: JCO precision oncology

Published: September 26, 2025

ESR1 analysis of liquid biopsy in breast cancer, one-year routine experience of an Italian clinical referral center.

ESR1 analysis of liquid biopsy in breast cancer, one-year routine experience of an Italian clinical referral center.

Journal: The journal of liquid biopsy

Published: September 16, 2025

Machine learning prediction of germline BRCA1/2 pathogenic variants in patients with ovarian cancer.

Machine learning prediction of germline BRCA1/2 pathogenic variants in patients with ovarian cancer.

Journal: BMJ health & care informatics

Published: August 06, 2025

Showing 1-12 of 160

Last Updated: 09/26/2026